Background-A simple and effective heart failure (HF) risk score would facilitate the primary prevention and early diagnosis of HF in general practice. We examined the external validity of existing HF risk scores, optimized a 10-year HF risk function, and examined the incremental value of several biomarkers, including N-terminal pro-brain natriuretic peptide. Inclusion of N-terminal pro-brain natriuretic peptide improved the overall classification of recalibrated Framingham, recalibrated Health ABC, and ARIC risk scores by 18%, 12%, and 13%, respectively. In contrast, cystatin C or highsensitivity C-reactive protein did not add toward incremental risk prediction. Conclusions-The ARIC HF risk score is more parsimonious yet performs slightly better than the extant risk scores in predicting 10-year risk of incident HF. The inclusion of N-terminal pro-brain natriuretic peptide markedly improves HF risk prediction. A simplified risk score restricted to a patient's age, race, sex, and N-terminal pro-brain natriuretic peptide performs comparably to the full score (area under curve, 0.745) and is suitable for automated reporting from laboratory panels and electronic medical records. (Circ Heart Fail. 2012;5:422-429.)
ach year approximately 500 000 individuals are diagnosed with heart failure (HF) for the first time in the United States. 1 In the setting of advances in clinical manage ment, the incidence as well as the prevalence of HF have increased. 2 Although progress in the therapy of HF appears to be associated with improved survival, greater efforts are needed toward early detection of ventricular dysfunction and the prevention of symptomatic HF. 3 
Clinical Perspective on p 429
Most patients with HF present for the first time and are managed by general practitioners. 4 However, both a poor appreciation of the importance of early diagnosis and treatment of left ventricular dysfunction 5 and poor confidence in establishing HF diagnosis 6 may be important barriers to HF management. Appropriate risk stratification tools 7 can alert the clinician to patients at high risk of development of HF long term allowing for their risk factors to be aggressively managed at the same time as still primarily under primary care. A risk prediction score that is parsimonious, based on information easily available to the general practitioner, and effective is required to implement the American College of Cardiology Foundation/ American Heart Association Guidelines for the Diagnosis and Management of Heart Failure in Adults (2009 update). 8 We examined the external validity of the extant HF risk scores, that is, the Framingham Heart Study 9 and Health ABC 10 scores, in the large, biracial cohort of middle-aged participants sampled from 4 US communities by the Atherosclerosis Risk in Communities (ARIC) Study. We also derived a parsimonious HF risk function focused on primary care settings, called here the "ARIC HF risk score," and gauged its performance relative to the Framingham and Health ABC functions in predicting the 10-year risk of HF. Given the increasing use of biomarkers in clinical settings, we also examined the incremental value of few biomarkers, including N-terminal pro-B-type natriuretic peptide (NT-proBNP), for the long term risk prediction of HF.
Methods

Study Population
The ARIC Study enrolled 15 792 men and women ages 45 to 64 years sampled from 4 US communities. 11 Baseline examinations of the cohort were conducted from 1987 to 1989 to collect standardized information on socioeconomic indicators, medical history, family history, cardiovascular risk factors, serum chemistries, electrocardiograms (ECGs), and medication use. Three re-examinations, annual telephone interviews, and active surveillance of hospitalizations and death followed the baseline visit. The last complete cohort visit was done in 1996 to 1998.
Analysis involved use of covariates at 2 different index visits, that is, at the baseline examination (1987) (1988) (1989) and at Visit 4 (1996 Visit 4 ( -1998 . For analyses using baseline data, those with prevalent HF (n=775) or missing (n=325) data on HF 12 ; missing information on any of the predictors shown in Table 1 (n=1502); or race other than black or white (n=48) were excluded, thus leaving a cohort of 13 555 observations for analysis. After derivation of the ARIC HF model, we compared the β estimates and discrimination statistics with those from a data set that excluded observations with missing information only for variables included in the final model (n=279); all estimates were found to be quite similar.
Several biomarkers included in these analyses were assayed from stored specimens from this last visit (Visit 4). From the 11 656 cohort members examined at the ARIC field centers during Visit 4, those with prevalent HF at the baseline visit (n=469) and those with incident HF between the baseline visit and Visit 4 (n=227) were excluded; those not self-identified as black or white (n=31) and those missing any important covariate (n=187) or NT-proBNP (n=327) or NT-pro-BNP values ≥6025 pg/mL (n=6) were excluded, thus leaving a sample of 10 106 for the analyses using Visit 4 as the index visit.
Predictors of HF
Prevalent coronary heart disease was ascertained from the medical history as well as the adjudicated baseline ECG. After 5 minutes of rest and while seated, blood pressure was measured 3 times using a random-zero sphygmomanometer, and an average of the last 2 readings was taken. Serum glucose was measured using the hexokinase method. Diabetes was defined by the presence of any serum glucose level ≥200 mg/dL, an 8-hour fasting glucose level ≥126 mg/ dL, a self-reported history of diabetes, or the current use of medications for diabetes. Cigarette smoking status was defined as selfreported current smoking. The self-reported average number of cigarettes/day and numbers of years of smoking were multiplied to derive cigarette-years of smoking, and this number was divided by 20 to get pack-years of smoking. Chronic obstructive pulmonary disease was defined as a self-report of physician diagnosis of either emphysema or chronic bronchitis (or a chronic lung disease when using Visit 4 as baseline). Body mass index was defined as the ratio of measured weight (in kilograms) and measured height 2 (in meters 2 ). Race and was identified at baseline as white, black, Native American or Alaskan Indian, or Asian or Pacific Islander.
An auscultatory finding of either a diastolic murmur or a systolic murmur of Grade 4 or above by a trained physician assistant was considered positive for presence of valvular heart disease. A supine 12-lead ECG at rest was obtained using the MAC PC10 personal cardiogram (Marquette Electronics, Milwaukee, WI). Processing, monitoring, and quality control of the ECG data have been described elsewhere. 13 The presence of left ventricular hypertrophy was defined as a Cornell voltage >28 mm in men or >22 mm in women when using a 12-lead resting ECG. QRS duration (derived from 10-second resting ECG) of >120 ms as commonly used in clinical settings to define bundle branch block was used as a binary variable.
In addition to NT-proBNP, 2 biomarkers putatively predictive of HF were considered. Using stored samples from Visit 4 (1996-1998), high-sensitivity C-reactive protein using the immunoturbidimetric assay, 14 cystatin C using particle-enhanced immunonephelometry, 15 and NT-proBNP using the Elecsys proBNP II immunoassay 16 were assayed.
Characterization of HF
Incident HF was defined as the first HF hospitalization or presence of HF code on the death certificate since the baseline visit through 2007. These events were identified from hospital discharge records and death certificates that showed a HF code in any position. International Classification of Diseases Code, Ninth Revision (ICD-9) code 428.x and deaths with ICD-9/10 codes of either 428.x or I50 were considered as HF. The percent agreement between HF events adjudicated by a standardized physician panel and ICD-9 code 428.x at any position was 73%, similar to that with the Framingham HF criteria (70%).
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Statistical Methods
The following analyses were done using SAS Version 9.2 statistical software (SAS Institute, Cary, NC). Means (SDs) and proportions of characteristics at baseline were estimated by incident HF status. Cox proportional hazard models were used to estimate age, race, and sex-independent hazard ratios for presence versus absence (categorical variables) or per SD increment (for continuous variables). Those without incident HF were censored at death or at the end of study follow-up. Model performance measures such as area under the receiver operating characteristic curve (AUC) was estimated for discrimination and Gronnesby-Borgan statistics 18 for model fit. Also, log likelihood ratio χ 2 statistics were estimated by subtracting −2 log likelihood of the model containing age, race, sex, and each variable from −2 log likelihood of a model with age, race, and sex only. Because net reclassification improvement (NRI) may be more meaningful for clinical decision-making than the AUC, 19 it was estimated for cutoffs for 10-year risk (<5%, 5 to <10%, 10 to <20%, and ≥20%). 19, 20 All the variables presented in Table 1 with the exception of sex and race were retained when using the likelihood ratio χ 2 test with backward elimination exit criteria probability value of 0.1. AUC, NRI, and integrated discrimination improvement were estimated by methods that allow these to vary by time and that account for censoring. 21 The variables considered in optimizing an HF risk score in ARIC are shown in Table I in the online-only Data Supplement. To test the external validity of the extant risk functions in the ARIC study population, we estimated each participant's risk score by multiplying the published regression coefficients from the extant risk functions 9,10 by the respective measurements for the ARIC cohort members. A Cox regression model was then fit with the risk function as the sole independent variable and performance statistics were estimated. Model fits for 5 and 10 years of follow-up yielded estimates that were quite similar. For the estimation of performance statistics of extant scores, we used both published regression coefficients 9, 10 and regression coefficients derived within the ARIC cohort using the variables in the respective risk scores.
To derive the ARIC risk function, we computed AUC for multiple models starting with variables that contributed most to AUC independently at the same time as considering their easy availability to the primary care practitioners and measurement quality characteristics in practice settings.
To test the incremental value of NT-proBNP to the performance of the ARIC study risk score, we considered NT-proBNP and its log Log likelihood ratio χ 2 statistics calculated by subtracting −2 log likelihood of respective model from the −2 log likelihood of a model with age, race, and sex only (Akaikes information criterion, 27153.8).
HR indicates hazard ratio; AUC, area under the curve of a receiver operating function; LR, likelihood ratio; GB, Gronnesby-Borgan; ARIC, Atherosclerosis Risk in Communities; HF, heart failure; NT-proBNP, N-terminal pro-brain natriuretic peptide; BP, blood pressure; CHD, coronary heart disease; HDL, high-density lipoprotein; COPD, chronic obstructive pulmonary disease (self-report of a physician diagnosis); LDL, low-density lipoprotein.
*Expressed as mean and SD or percentages. †Each row represents a model. For variables other than age, models includes age as a simultaneous independent variable; hazard ratios contrast the presence of a categorical characteristics versus its absence or 1 SD unit increase in the continuous variable, independent of age. For variables other than race and sex, model contains age, race, and sex. Thus, the incremental AUC is as compared to a model with only age, race, and sex.
‡AUC is calculated over 10 y of follow-up (not corrected for optimism). §GB test has 9 degrees of freedom corresponding to 9 indicator variables to represent deciles. ||Model has only age as an independent variable. ¶Model has age and the corresponding variable. **Measured at Visit 4 (1996-1998) and the incremental AUC is compared with a model with age, sex, and race fitted with Visit 4 as baseline and estimates 10-y risk.
transformation after exclusion of 6 observations with NT-pro-BNP values ≥6025 pg/mL, which on examination were considered influential outliers. We evaluated models linear in NT-proBNP, polynomial in NT-proBNP, piecewise linear in NT-proBNP, categorical with 6 categories (percentiles 20, 40, 60, 80, 90) and categorical with 7 categories (20, 40, 60, 80, 90, and 95), linear in log (NT-proBNP), polynomial in log (NT-proBNP), and piecewise linear in log (NTproBNP). The comparative fit of these models is summarized in Figures IA and IB in the online-only Data Supplement and the comparative index of discrimination in Table II in the online-only Data Supplement. Given its fair discrimination performance, model fit, and simplicity of use, log (NT-proBNP) was chosen for these analyses, although it is not the best fitting transformation at the lower tail of the distribution.
To obtain stable estimates for AUC corrected for optimism, due to fitting the risk score in the sample from which it was derived, 1000 bootstrap samples were processed to achieve stable estimates with lower bias than split sample and crossvalidation. 22 The average optimism, that is, (measure bootstrap samples -measure original data set ) was subtracted from the original performance measure.
Role of the Funding Source
The ARIC Study is carried out as a collaborative study supported by contracts from the National Heart, Lung, and Blood Institute, National Institutes of Health. Roche Diagnostics provided reagents and the loan of an instrument to conduct the assays of NT-proBNP. Neither of these agencies had any role in design, analysis, or interpretation of this study.
Results
Derivations of the ARIC HF Risk Score
Based on an average of 15.5 years of follow-up since baseline, 1487 (11%) incident HF events were observed in the 13 555 cohort members. The characteristics of study participants at baseline by incident HF status as well as age, race, and sex-adjusted hazard ratios, AUC, and Gronnesby-Borgan statistics of models for each additional variable are presented in Table 1 . Briefly, NT-proBNP, diabetes, blood pressure-lowering medication use, and body mass index each contributed >0.03 to the AUC of a model that included age, race, and sex only (AUC, 0.673).
Next we compared the AUC of several multivariable models to predict 10-year risk of HF, detailed in Table I in the online-only Data Supplement. The main criteria in the selection of candidate variables and model building were (1) easy availability of the measurements to primary care physicians; (2) measurement reliability; and (3) parsimony relative to the degree of improvement in the AUC. Based on this, the optimal model in the prediction of 10-year HF risk in the ARIC population included age, race, sex, prevalent coronary heart disease, systolic blood pressure, use of blood pressure-lowering medication, diabetes, smoking status, heart rate, and body mass index. After correction for optimism, the AUC achieved by this model was 0.7937 (95% CI, 0.7932-0.7942). Figure  II in the online-only Data Supplement displays the predicted and observed events in the ARIC cohort from the ARIC risk function by deciles of risk prediction score. Although <5% of the cohort members below the 50th percentile had an HF event in 10 years, >30% of cohort members in the highest decile had an HF event. The ratio of predicted probability of those in the highest decile as compared with those in the lowest decile was 24.8, and the absolute 10-year risk difference was 31.2%.
The variables included in the HF risk score to predict 10 years of HF risk and their regression coefficients (log of hazard ratio of HF) are shown in Table 2 for all participants and by race and sex. Similarly, we have included yearly estimates from the baseline survival function in Table III in the online-only Data Supplement. Modest variability in the magnitude and direction of associations can be seen by race and sex but there is limited statistical power to differentiate these associations in subsets of the cohort. The plots of 10-year risk of HF versus percentile of risk shown in the Figure depict the overall goodness of fit achieved. We explored several fits for NT-proBNP on HF as an outcome. Although the fit was improved in piecewise models, the discrimination achieved was similar. Analysis repeating the piecewise linear fit (in log [proBNP]) after changing the lowest and highest knots to 10/90 percentiles of cases instead of 5/95 showed negligible differences in performance. Table 3 presents the AUC and model fit statistics for the ARIC and the Framingham and the Health ABC risk functions based on models fit to predict the 10-year risk of HF. The AUC for the Framingham and the Health ABC risk scores were estimated using the published β estimates from the respective cohorts as well as with β coefficients estimated in the ARIC cohort using the variables of the respective risk scores as described in the "Methods" section. The AUC from the ARIC HF risk function was highest at 0.7966; the AUCs estimated in the ARIC cohort using variables from the Framingham HF risk score (0.7618) and using the variables in the Health ABC risk score (0.7835) were lower. The AUCs estimated using published coefficients from the Framingham and the Health ABC HF risk scores were 0.6139 and 0.7848, The ARIC study cohort's Visit 4 (1996-1998) was used to predict risk of HF through 2007. The categorical variables such as black, male, BP-lowering medication use, diabetes, prevalent CHD, current smoker, former smoker were coded as 1 if condition was present and 0 if absent. For continuous variables, the absolute value was used. All the variables were statistically significant (P <0.05) for prediction of HF.
External Validation of Extant Risk Scores and Comparison With the ARIC Risk Score Model
ARIC indicates Atherosclerosis Risk in Communities; NT-proBNP, amino terminal pro-B type natriuretic peptide; BP, blood pressure; CHD, coronary heart disease.
respectively. Reclassification using the ARIC HF risk score improved the overall classification of the individuals classified by the Framingham HF risk score: the net improvement score subtracting off the percentage of worsening classification from the percentage of improving classification was 13.5%. The gains in reclassification using the ARIC risk score relative to that of the Health ABC risk score (which includes additional variables) were modest (NRI, 3%). The
Figure.
Predicted 10-year risk of heart failure versus percentile of risk for models parameterized as follows: demographic model-age, race, and sex; demographic model+log (proBNP)-age, race, sex, log (NT-proBNP); ARIC basic model-age, race, sex, prevalent CHD, diabetes, systolic blood pressure, blood pressure medication use, heart rate, smoking status, and BMI; ARIC basic model+log (proBNP)-age, race, sex, prevalent CHD, diabetes, systolic blood pressure, blood pressure medication use, heart rate, smoking status, BMI, and log (NT-proBNP). Pro-BNP indicates pro-brain natriuretic peptide; NT-proBNP, N-terminal pro-brain natriuretic peptide; ARIC, Atherosclerosis Risk in Communities; CHD, coronary heart disease; BMI, body mass index. V1 and V4 refer to use of elements from the ARIC cohort's field center visits, that is, Visit 1 (1987 Visit 1 ( -1989 and Visit 4 (1996 Visit 4 ( -1998 , respectively. V4 was used as baseline in estimations involving NT-proBNP. The no. of participants when using V1=13 555 and using V4=10 103. The variables included in the Framingham HF risk score 9 are age, sex, CHD, diabetes, ECG-based left ventricular hypertrophy, valve disease, heart rate, and systolic blood pressure. Health ABC score 10 includes the Framingham study variable with the following differences: added serum albumin, serum creatinine, and smoking status; replaced glucose for diabetes; removed valve disease. The ARIC basic HF risk score includes age, race, sex, CHD, diabetes, systolic blood pressure, blood pressure medication use, heart rate, smoking status, and body mass index. AUCs are corrected for optimism. The GB statistics for all the models presented was <0.01.
ROC indicates receiver operating characteristic; ARIC, Atherosclerosis Risk in Communities; NT-proBNP, amino terminal pro-B type natriuretic peptide; HF, heart failure; CHD, coronary heart disease; ECG, electrocardiogram; AUCs, areas under the curve. overall goodness of fit by decile of risk score was good for the 3 risk functions, although the large number of events led to sensitivity of the Gronnesby-Borgan test.
Incremental Value of Biomarkers
With Visit 4 as baseline, the average follow-up was 9.6 years, yielding 870 incident HF events in the 10 109 followed through 2007 (8.6%).
High-sensitivity C-reactive protein did not contribute appreciably to the prediction of HF beyond that of a model with age, race, and sex only (AUC, 0.668 versus 0.663) nor relative to the ARIC HF risk model (AUC, 0.772 without versus 0.775 with high-sensitivity C-reactive protein), which yielded an NRI of 0.4%. Similarly, cystatin C did not improve the ability to predict the 10-year risk of HF compared with the model with age, race, and sex only (AUC, 0.668 versus 0.672) nor to the ARIC HF risk model (0.772 without versus 0.779 cystatin C; NRI of 3.2%). These 2 biomarkers were not considered further.
Of all the variables shown in Table 1 , NT-proBNP had the largest contribution to the AUC once added to a model based on the 1996 to 1998 examination data containing age, sex, and race (data not shown). The AUC of the model that included age, race, sex, and NT-proBNP was 0.745. NT-proBNP was modeled using several distribution-based approaches to the treatment of NT-proBNP, as shown in Figures IA and IB in the online-only Data Supplement; the resulting indices of discrimination and of fit of these models can be seen in Table II in the online-only Data Supplement. For ease of replication and use in practice, the log transformation of NT-proBNP was selected for further analyses.
The AUC of the ARIC HF risk score model (basic) compared with this model with the addition of NT-proBNP is shown in Figure III The NRI after the addition of NT-proBNP was 13% (95% CI, 10.2%-19.9%) as shown in Table 4 
Discussion
We optimized a parsimonious linear combination of variables to estimate the 10-year risk of incident HF in a population sample of men and women aged 45 to 64 years based on information readily available in primary care settings. Compared with the extant HF risk scores, this ARIC HF risk function includes fewer variables and performs better than the Framingham abbreviated model and comparably to the Health ABC HF prediction model in terms of discrimination using both traditional (AUC) and newer measures (NRI). Overall, the goodness of fit across deciles of risk was satisfactory. Addition of NT-pro BNP increased the AUC of the ARIC HF model by 0.03. Considering that the AUC of the ARIC HF model was already high at 0.77, addition of this biomarker achieves a notable improvement relative to what is commonly seen in the literature after addition of multiple predictor variables.
HF is a heterogeneous syndrome and often the culmination of prolonged and complex pathological processes. 23 In this respect, the robust discrimination ability for HF is remarkable and comparable if not higher than the AUC statistics generally observed in coronary heart disease risk prediction, especially among women. The Framingham HF risk score did not perform well in this sample, even when restricted to characteristics similar to the original derivation cohort (data not shown); in contrast, the discrimination achieved by the Health ABC risk score was good. The derivation cohorts for these risk scores are different, that is, unselected middle-aged participants in ARIC, a selected cohort of healthy elderly in the Health ABC, and a cohort with selective comorbidities in the Framingham HF risk score. The Health ABC risk score was validated in the Cardiovascular Health Study (CHS) cohort 25 ; although the Health ABC cohort includes blacks, race was not included as a variable in the reported risk score.
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The addition of NT-proBNP to risk models markedly improved 10-year HF risk prediction. Remarkably, the AUC of a model restricted to age, sex, race, and NT-proBNP is comparable to the AUC statistics achieved for most multivariable risk prediction equations. These results open the prospect of simple, automated estimates of the 10-year risk of HF to accompany the NT-proBNP values reported by clinical laboratories, similar to the current practice of automated reporting of an estimated glomerular filtration rate with measurements of serum creatinine.
Although age and sex are almost invariably recorded and thus available, race may be missing in the electronic medical records and administrative claims data. We therefore estimated the impact of race on the performance of the full and the "simplified" ARIC models. In the "simple" model (based only on age, sex, log NT-proBNP), the AUC was 0.7369 compared with an AUC of 0.7412 on addition of race (an increment of 0.0043). The risk in the highest decile-lowest decile for the former model was (28.5%-1.5%=27%) compared with (29.1%-1.5%=27.6%). Similarly, for a model with age, sex, diabetes, hypertension (clinically diagnosed), and current smoking, the AUC was 0.7428 compared with the AUC of the same model after the addition of race at 0.7437 (an increment of 0.0009).
Last, for the optimized ARIC risk score model with age, sex, diabetes, hypertension, systolic blood pressure, heart rate, body mass index, and current and former smoking, the AUC was 0.7734 compared with the AUC of 0.7733 for the same model with the addition of race (essentially unchanged).
Other measurements commonly available in clinical settings such as ECG-defined left ventricular hypertrophy and the QRS interval and serum markers such as creatinine, albumin, and high-density lipoprotein cholesterol did not contribute importantly to the AUC for HF prediction, possibly reflecting saturation of the models, intermediate variable effects, modest collinearity with variables already in the model, or a low prevalence in this population-based cohort. Other proxy measures of fat mass such as waist circumference or waist-to-hip ratio may provide a similar predictive value as body mass index. These were not considered due to the widespread use of body mass index in clinical settings and the higher measurement error associated with the other measures.
Convenient access to the predictor variables in the risk score, ease of use, parsimony in the number of predictor variables, and the ability to modify the factors that adversely influence a patient's risk also seem influential for acceptability in clinical practice. A risk score with these characteristics that can penetrate clinical practice can serve to identify patients at intermediate or high levels of predicted risk of HF who may benefit from education, aggressive risk factor management, regularly scheduled visits, and timely use of diagnostic testing or referral to a cardiologist if felt necessary by the general practitioner. Current trends toward an increasing use of electronic medical records and availability of simple computational tools to practitioners may increase the penetrance and impact of risk estimation tools and research in this area will be needed. Prevention of the progression of Stage A HF to Stages B or C, as highlighted in the guidelines recently released by several professional organizations, 8, 26 will require an ability for simple and effective HF risk stratification in general practice. HF prevention trials that induct and monitor high-risk individuals also require such tools for initial screening and stratification of those eligible.
Among the strengths of this study is the derivation of a risk score in a large community-based cohort of middle-aged white and black men and women with long-term follow-up and high retention rates. There are several limitations also worth noting. Although similar to that of the Health ABC study and other cardiovascular disease cohorts, the classification of HF as the outcome was not validated by review of all possible events. A recent validation study based on a large sample of hospitalizations discharged with ICD codes with high suspicion of HF indicates that the positive predictive value of an ICD code 428.x for HF classified by a physician review panel was 77% and the sensitivity was 95%. 17, 27 The corresponding positive predictive value and sensitivity of Framingham HF criteria were 0.78 and 0.83, respectively. 17, 27 Thus, the HF outcome based on hospital discharge ICD codes used in our analyses may be considered at least as good as the Framingham HF diagnostic criteria. However, it should be noted that our study would miss HF cases managed successfully in outpatient settings if they were not hospitalized throughout the 15.5-year follow-up period, although this would probably apply to rather small numbers. We must also note that little echocardiography data were available over the extended course of this cohort's follow-up as a result of which we were unable to consider the potentially different predictors for systolic versus diastolic HF.
We conclude that the ARIC HF risk score performs well in predicting 10-year risk of hospitalized HF in community settings. The inclusion of NT-proBNP in the ARIC HF risk score-and even in a model restricted to age, sex, and racemarkedly improves the prediction of 10-year risk of HF in middle-aged adults. These findings need replication and possibly calibration in other cohorts. The risk calculators presented are available on www.ARICNEWS.net. Practice-based tools for early identification of susceptibility to HF and its efficient monitoring in community settings may contribute to the reduction of the growing burden of HF by enabling proactive risk management.
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